[The status of imaging methods for the treatment of patients with Parkinson's syndrome].
The accuracy of the diagnosis of Parkinson's disease early in the course of the disease remains a clinical challenge. Imaging of dopamine transporters with DatSCAN and SPEC tomography contributes to identifying patients without nigral degeneration and thus helps preventing unnecessary and potentially harmful treatments. The cost of these imaging procedures needs to be set against the cost of unnecessary medication.
Schwarz
J
J
Klinik und Poliklinik für Neurologie, Universität Leipzig. johannes@caltech.edu
Gratz
S
S
Hahn
U
U
Förstl
H
H
Jarnig
M
M
D003362:Cost-Benefit Analysis; D015259:Dopamine Agents / Q000191:economics / Q000627:therapeutic use; D050483:Dopamine Plasma Membrane Transport Proteins / Q000032:analysis / Q000378:metabolism; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D049268:Positron-Emission Tomography / Q000191:economics; D012680:Sensitivity and Specificity; D013378:Substantia Nigra / Q000473:pathology; D015899:Tomography, Emission-Computed, Single-Photon / Q000191:economics
D015259:Dopamine Agents; D050483:Dopamine Plasma Membrane Transport Proteins